Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma.
about
Photodynamic therapy: one step ahead with self-assembled nanoparticlesInteractions of nanomaterials and biological systems: Implications to personalized nanomedicinePolymer-drug conjugates: recent development in clinical oncologyA single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas.Polymeric conjugates for drug deliveryTumour targeting: biological factors and formulation advances in injectable lipid nanoparticles.Cellular delivery of doxorubicin via pH-controlled hydrazone linkage using multifunctional nano vehicle based on poly(β-l-malic acid)Melanoma growth effects on molecular clearance from tumors and biodistribution into systemic tissues versus draining lymph nodes.Polymer conjugates as anticancer nanomedicines.Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review)Prodrug strategies in anticancer chemotherapy.Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate.Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.Multifunctional Poly(ethylene glycol)s.Objective: tumor. Strategies of drug targeting at the tumor mass level.PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination.Strategies to release doxorubicin from doxorubicin delivery vehicles.Polymer therapeutics at a crossroads? Finding the path for improved translation in the twenty-first century.Complexation of cell-penetrating peptide-polymer conjugates with polyanions controls cells uptake of HPMA copolymers and anti-tumor activity.Block co-polymer nanoparticles with degradable cross-linked core and low-molecular-weight PEG corona for anti-tumour drug delivery.Establishment of subcellular fractionation techniques to monitor the intracellular fate of polymer therapeutics I. Differential centrifugation fractionation B16F10 cells and use to study the intracellular fate of HPMA copolymer - doxorubicin.HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines.Polymer therapeutics designed for a combination therapy of hormone-dependent cancer.Repurposing Drugs in Oncology (ReDO)-nitroglycerin as an anti-cancer agent.Gamma scintigraphy of a 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma.Systemic Delivery and Biodistribution of Cisplatin in Vivo.Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumour agent.Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470.Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy.Polymer therapeutics and the EPR effect.The Light at the End of the Tunnel-Second Generation HPMA Conjugates for Cancer Treatment.Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice.Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues.Reduction of the side effects of an antitumor agent, KRN5500, by incorporation of the drug into polymeric micelles.
P2860
Q28083513-A1FA37BD-B75D-4A39-BC61-13D37858DD7AQ28391849-906C2AAC-0471-4E89-BE73-61ADA12828B6Q34656003-A5DFB468-60E1-41E7-99D9-C28C11B4136EQ35130646-89931EEE-65C6-43B8-B650-EEF2EC797595Q36029175-A84F59E0-24BB-459B-947B-19623299954AQ36098273-A0E7223A-F035-4FF4-ACE7-68BB56D0D23BQ36321843-5A3F3B71-9784-44BD-A5C7-16DF982CDA5DQ36494851-51CC25C2-1F9E-4462-8E84-D02C8EFEA5CEQ36561667-1C7AAA9E-901F-4500-A982-934548FF2628Q36643541-70800DFE-1C6C-4295-A35F-2DBC71B4387DQ36982570-87703F86-1275-4D68-984D-CAB554AF9ED7Q37034326-7C9294F5-7CD9-41D6-BF6C-7D80720C2C66Q37467770-2B63A831-DF01-4DF1-9BF6-0B97BBF5F32EQ37900556-B100CF13-EA76-44AE-936E-EE54F4EF2C64Q38120976-697DC8BE-CCF3-49A8-99DA-2CA17946297BQ38281206-FA94769E-5BAD-4CC6-85D8-EEFD1CA8040CQ38643071-A903C04D-CFAD-47B4-8A51-FEF1997E3A53Q38645927-C837A9A8-B928-4432-BD7A-5823B38C8B8AQ39098106-E3576447-A28B-4818-93C7-7B38DB44F1F3Q39690147-8DE77C09-4457-47C1-AA13-225BC1427F4AQ40210618-B7E0B8AE-53CA-43D3-B757-1235B51DFFB9Q40342855-A1222003-9494-428F-BD6D-90D2462B5D9BQ40418110-A6F28E14-5A6F-4B68-B1A0-1D7CAE82BC37Q40468319-3F801FD3-3C21-4EAB-B2AD-B211A4770E71Q40957297-0FBCEC0E-F279-47A2-B2ED-6539D39470FEQ41057240-A2486893-A419-4EE0-A1C6-780FD8ACA7A1Q43845018-D76B9E89-75D6-4B70-855D-4ACF7E759B49Q44775111-5DEF3B02-C318-47A0-BC66-E3131D880545Q45869931-DCAC3923-9127-4737-B1FE-ABFE16052986Q47681427-792F3F3B-1740-4F52-B774-3FD56868F0BFQ48558433-E0E4547B-9F6B-4005-B103-6E4C0B76360DQ51983020-3C0D4DC5-AB67-4C86-9350-6700A420D240Q54951534-F369A5EA-CF17-449D-B5DD-6D873D9EC09CQ55246031-9E37BE3E-F0B3-4AD1-8295-233F93876C3E
P2860
Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Tumour tropism and anti-cancer ...... aneous murine B16F10 melanoma.
@en
Tumour tropism and anti-cancer ...... aneous murine B16F10 melanoma.
@nl
type
label
Tumour tropism and anti-cancer ...... aneous murine B16F10 melanoma.
@en
Tumour tropism and anti-cancer ...... aneous murine B16F10 melanoma.
@nl
prefLabel
Tumour tropism and anti-cancer ...... aneous murine B16F10 melanoma.
@en
Tumour tropism and anti-cancer ...... aneous murine B16F10 melanoma.
@nl
P2093
P2860
P356
P1476
Tumour tropism and anti-cancer ...... aneous murine B16F10 melanoma.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1994.363
P407
P577
1994-10-01T00:00:00Z